JAK2 Essential Thrombocythemia (ET) Treatment

Posted by goodcheers @goodcheers, 1 day ago

I recently came upon a fairly recent article about the monoclonal antibody INCA44989 treatment for JAK2 ET. It supposedly has a roughly 70% positive response rate, and with a low toxicity profile, meaning minimal side affects. This is great news for all of us who have been afflicted with this unfortunate blood disorder.

I searched for a discussion about this but nothing came up. I'm wondering if anyone reading this may have some experience or information on this subject.

Thanks

Interested in more discussions like this? Go to the Blood Cancers & Disorders Support Group.

janemc | @janemc | 1 day ago

Intriguing! Could you supply a link to the article you read, goodcheers?

Google AI found this comment:

NCA033989 (formerly referred to in early development as INCA44989) is a first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody currently in clinical trials for essential thrombocythemia (ET). It targets the underlying drivers of the disease rather than just managing symptoms.

. . . please note, this antibody is being tested for those with the CALR driver (rather than the JAK driver).

If you go to the top of this page and in the search box type "drbart86" -- you will meet someone actively participating in this trial.

It is VERY exciting indeed!

janemc | @janemc | 1 day ago

From Targeted Oncology:

A New Era for ET: Targeting the CALR Mutation
Author(s)Sabrina Serani, Aaron T. Gerds, MD, MS
September 4, 2025

Please sign in or register to post a reply.